CAMBRIDGE, Mass., March 31, 2026
Enveric Biosciences has strengthened its position in the rapidly evolving neuropsychiatric drug development space with the issuance of a new U.S. patent covering its EVM301 Series of neuroplastogenic drug candidates, marking a significant advancement in its intellectual property (IP) portfolio. Granted by the United States Patent and Trademark Office on March 17, 2026, the U.S. Patent No. 12,577,232 provides expanded protection for non-hallucinogenic, next-generation therapeutics aimed at treating a broad spectrum of psychiatric and neurological disorders, including depression, anxiety, and addiction. This milestone underscores Enveric’s strategy to develop innovative, safer alternatives to traditional psychedelic-based therapies while maintaining strong commercial defensibility through robust patent coverage.
Patent Strengthens Neuroplastogenic Innovation Pipeline
The newly issued patent, titled “N-heterocycle substituted tryptamine derivatives and methods of using,” significantly enhances Enveric’s IP estate by covering novel chemical compounds, pharmaceutical formulations, and therapeutic applications related to its EVM301 Series. These compounds are designed to promote neuroplasticity—the brain’s ability to reorganize and form new neural connections—without inducing hallucinogenic effects, a major limitation associated with first-generation psychedelic therapies.
This patent builds upon Enveric’s previously granted U.S. Patent No. 12,338,231, collectively expanding protection for its proprietary tryptamine-based molecular platform. With 27 issued U.S. patents and approximately 60 pending applications globally, the company is establishing a comprehensive and defensible intellectual property framework that supports long-term innovation and commercialization opportunities. The expanded claims further reinforce Enveric’s leadership in the development of non-hallucinogenic neuroplastogens, an emerging class of therapeutics poised to transform mental health treatment paradigms.
Lead Candidate EB-003 Targets Depression and Anxiety
Advertisement
At the forefront of the EVM301 Series is EB-003, Enveric’s lead drug candidate, which is being advanced toward an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration. EB-003 is a dual-acting 5-HT2A and 5-HT1B receptor modulator, uniquely engineered to deliver rapid and durable antidepressant and anxiolytic effects without the hallucinogenic side effects typically associated with serotonergic compounds.
By selectively targeting these serotonin receptors, EB-003 aims to unlock the therapeutic benefits of neuroplasticity while maintaining outpatient convenience and safety, a critical factor for widespread clinical adoption. The compound’s mechanism is designed to stimulate neural rewiring and resilience, offering a promising approach for patients with treatment-resistant depression and anxiety disorders, where current therapies often fall short.
Enveric’s focus on precision neuropharmacology aligns with growing scientific evidence supporting the role of neuroplasticity in mental health recovery. As psychiatric disorders continue to rise globally, the demand for fast-acting, durable, and well-tolerated therapies is intensifying, positioning EB-003 as a potential next-generation solution in CNS therapeutics
Strategic IP Expansion Drives Future Clinical Growth
The issuance of the ‘232 patent represents more than just legal protection—it serves as a strategic enabler for clinical and commercial expansion. By securing broad claims across chemical structures and therapeutic methods, Enveric is enhancing its ability to attract partnerships, secure funding, and accelerate clinical development timelines.
The company remains focused on advancing EB-003 into first-in-human Phase 1 clinical trials, a critical milestone that will validate its safety and pharmacological profile in humans. With a strong IP foundation and a differentiated scientific approach, Enveric is well-positioned to capitalize on the growing interest in neuroplastogenic therapies that avoid the regulatory and safety challenges of psychedelics.
Furthermore, Enveric’s platform extends beyond a single candidate, encompassing a diverse pipeline of novel small molecules targeting multiple neuropsychiatric and neurological indications. This scalability enhances the company’s potential to deliver multiple high-impact therapies while maintaining competitive advantage through its expanding patent estate.
As the mental health crisis continues to demand innovative solutions, Enveric’s latest patent achievement reinforces its commitment to transforming the treatment landscape through science-driven, patient-centric innovation. The combination of strong intellectual property, differentiated mechanisms, and clinical advancement positions the company as a key player in the future of neuropsychiatric drug development.
Source: Enveric Biosciences press release
